WHERE ARE YOU?

Concept Pre-Sub Submission prep Newly cleared Raising Postmarket & security

THE TAPE

Elucid raises $55M Series D with FFR-CT 510(k) under FDA review Enovis to buy eCential Robotics for 155 million euros FDA authorizes Vitestro's Aletta, the first autonomous blood-drawing robot, five months after a $70M Series B Renata Medical raises $25M Series D to scale the Minima pediatric stent FDA opens a docket on how to regulate generative AI devices FDA clears Jupiter Endovascular's Vertex thrombectomy system for pulmonary embolism in 89 days FDA clears Wandercraft's Eve, the first self-balancing exoskeleton for home use Meduloc raises $4M Series B to start alpha launch of its nitinol fracture implant FDA sets FY2027 device user fees: $28,653 for a 510(k), $13,785 to register Elucid raises $55M Series D with FFR-CT 510(k) under FDA review Enovis to buy eCential Robotics for 155 million euros FDA authorizes Vitestro's Aletta, the first autonomous blood-drawing robot, five months after a $70M Series B Renata Medical raises $25M Series D to scale the Minima pediatric stent FDA opens a docket on how to regulate generative AI devices FDA clears Jupiter Endovascular's Vertex thrombectomy system for pulmonary embolism in 89 days FDA clears Wandercraft's Eve, the first self-balancing exoskeleton for home use Meduloc raises $4M Series B to start alpha launch of its nitinol fracture implant FDA sets FY2027 device user fees: $28,653 for a 510(k), $13,785 to register

Series A

Axoft raises $55M Series A for soft-material brain implants

MedDevice Startups Staff · Apr 29 · 1 min read · Via MassDevice

Axoft closed an oversubscribed $55M Series A on April 29, 2026. C.P. Group Innovation led. Alumni Ventures, Stanford President's Venture Fund, Hillhouse Investment and Gaorong Ventures participated. Total funding now exceeds $60M.

The implant is built from Fleuron, a polymer Axoft says is up to 10,000 times softer than the polyimide in existing implantable brain-computer interfaces. The company reports 11 or more patients implanted across trials, including the first four cases of its FINESSE study. Mass General Brigham is a clinical collaborator. CEO Paul Le Floch said the money funds expanded global trials, US regulatory work and a GMP manufacturing facility in Boston. Building GMP capacity at Series A is early. It signals Axoft intends to make its own probes rather than outsource them.

Questions & Answers

How much did Axoft raise in its Series A?

Axoft closed an oversubscribed $55M Series A on April 29, 2026, led by C.P. Group Innovation, taking total funding past $60M.

What is Axoft's Fleuron material?

Fleuron is Axoft's proprietary soft polymer for implantable brain-computer interfaces, which the company says is up to 10,000 times softer than the polyimide used in existing implants.

How many patients has Axoft implanted?

Axoft reported 11 or more patients implanted across multiple trials as of April 2026, including the first four cases of its FINESSE study.

← Back to Fundraising